Polymer use in Preservation of Tissue Perfusion to Address Sepsis

Perfusion Medical正在商业化一种名为PEG-20 k IV溶液的新型管道产品。的 公司认为这可能是第一种直接治疗败血症致命并发症的治疗方法， 因此，支持对疾病基本机制的新思考。脓毒症或脓毒性 综合征导致一系列疾病，在美国有170万人发生， 感染性休克每年导致超过27万美国人死亡。脓毒症，由 直接细菌感染或由受损内脏的脂多糖（LPS）泄漏引起 血液循环，产生免疫和非免疫反应的复杂级联。 这些最终导致多系统器官衰竭和死亡。没有药物 专门用于缓解败血症的任何潜在基础，而不是感染和来源 控制该公司声称，结合早期组织灌注的恢复， 败血症和破坏内皮细胞糖萼，将是一个全新的方法， 防止恶性循环和随之而来的致命的多器官衰竭。STTR涉及两个 目标。目的1将确定局部毛细血管灌注在LPS诱导和多微生物 腹膜炎诱导的败血性休克和PEG-20 k复苏的影响。研究人员将 试图证明与LPS或细菌性败血症相关的大量灌注缺损 被PEG-20 k IV溶液逆转，并且在脓毒症的早期过程中恢复灌注可以避免 多器官功能衰竭和死亡率。AIM 2将 确定脓毒症中糖萼的完整性和PEG-20 k复苏的效果。的 研究小组打算证明PEG-20 k非特异性结合并保护/重建 内皮糖萼在脓毒症和多器官衰竭，这限制了继发性细胞 炎症性终末器官损伤。在这项研究结束时，该公司将进行概念验证 数据显示败血性休克死亡率和器官衰竭的主要决定因素是次要的， 重要组织的严重灌注不良，早期用PEG-20 k纠正可以避免 灾难性的下游后果导致严重的疾病和死亡。如果成功， 解决方案将被证明是有效的，具有两种解决败血症的机制- 这将使PEG-20 k成为治疗产品的强有力的候选者。

Perfusion Medical is commercializing a novel pipeline product called PEG-20k IV Solution. The company believes this may be the first therapeutic to directly treat lethal complications of sepsis, and as such, support new thinking on the basic mechanisms of the disease. Sepsis or septic syndrome leads to a spectrum of illnesses and occurs at a frequency of 1.7 million people in the US each year and septic shock kills over 270,000 Americans each year. Sepsis, caused by direct bacterial infection or by leak of lipopolysaccharide (LPS) from a compromised splanchnic circulation, produces a complex cascade of immunological and non-immunological reactions. These ultimately lead to multiple systems organ failure and death. There are no medications specifically used to mitigate any underlying basis for sepsis other than infection and source control. The company asserts that the combination of restoration of tissue perfusion in early sepsis and breaking down endothelial cell glycocalyx, will be a radically new approach that prevents the vicious cycle and the attendant fatal multiple organ failure. The STTR involves two AIMS. AIM 1 will determine regional capillary perfusion in LPS-induced and polymicrobial peritonitis-induced septic shock and the effects of PEG-20k resuscitation. The researchers will seek to demonstrate that the massive perfusion defect associated with LPS or bacterial sepsis is reversed by PEG-20k IV solution and that restoring perfusion in early course of sepsis averts multiple organ failure and mortality by preserving vital tissue oxygen exchange. AIM 2 will determine the integrity of the glycocalyx in sepsis and the effect of PEG-20k resuscitation. The team intends to demonstrate that PEG-20k nonspecifically binds to and protects / rebuilds the endothelial glycocalyx during sepsis and multiple organ failure, which limits secondary cellular inflammatory end-organ injury. At the end of this study, the company will have proof-of-concept data showing that a major determinant of septic shock mortality and organ failure is secondary to severe malperfusion of vital tissues and that early correction with PEG-20k can avert devastating downstream consequences leading to critical illness and death. If successful, the solution will be shown to be effective with two mechanisms of addressing sepsis – either of which will make PEG-20k a strong candidate as a therapeutic product.